In preclinical studies, the MHC-I deficient tumors responded better to treatment of cytokine such as IL-12 and IL-18, raising the question of whether the efficiency of cytokine therapy relies on NK cells, considering the well-known role of NK cells in targeting MHC-I deficient tumor [79]. This evidence concerns the gene IL18 and neoplasm.